In the first half of this year, new drug acceptance volume of CDE reached a new high

Tao Jianhong said that compared with previous years, this year's growth rate is larger In the first half of 2014, the number of drugs accepted by CDE was more than 4500, up 22% compared with the same period last year Related to a large number of new drug acceptance, the drug review center (CDE) of the State Food and drug administration is also recruiting new personnel to expand the team of reviewers CDE announced last week that it plans to employ 20 drug reviewers of all kinds, including chemical pharmaceutical reviewers, chemical clinical reviewers, pharmacology and toxicology reviewers, biological product pharmaceutical reviewers and traditional Chinese medicine clinical reviewers Industry insiders said that the current review speed is far slower than the application speed After increasing the number of drug reviewers, the current situation that the CDE drug review progress is too slow is expected to be improved News extension: the growth rate of the total output value of China's pharmaceutical industry slows down Tao Jianhong, deputy director of the southern pharmaceutical economic office of the State Food and Drug Administration (CFDA), said at the fourth Development Forum on biological analogues that the growth rate of the total output value of China's pharmaceutical industry slows down, and with the deepening of the reform of the pharmaceutical system, the growth rate will be further adjusted At present, China's pharmaceutical market and economic environment are similar, Tao said In the first three quarters of 2014, China's GDP grew by 7.4% year-on-year, and the growth rate slowed down, especially in prescription drugs At present, 80% of the prescription drug market is through the channels of medical institutions Due to the existing problems such as "medical support by drugs", excessive medical treatment has increased the growth rate of the pharmaceutical industry With the deepening of the reform of public hospitals and the change of payment means, the phenomenon of drug abuse will gradually change, and the growth rate of the pharmaceutical industry will be adjusted to a rational level According to the data released by Southern Institute of pharmaceutical economics, from January to July 2014, the total output value of China's pharmaceutical industry reached 1287.8 billion yuan, a year-on-year increase of 16.1%, compared with a year-on-year increase of 18.8% in 2013, 20.1% in 2012 and 26.5% in 2011, and the growth rate has begun to slow down During the 11th Five Year Plan period, the total output value of the pharmaceutical industry remained at a high-speed growth level, with a compound growth rate of 24.03%